Literature DB >> 24857351

New IDH1 I113T mutation associated with BRAF V600E mutation: new driver of gliomagenesis?

E Tabouret1, F Fina2, F Vincentelli3, I Nanni2, D Figarella-Branger4.   

Abstract

BACKGROUND: IDH mutations and BRAF mutations are classically mutually exclusive and usually associated with infiltrative or circumscribed gliomas and glioneuronal tumors respectively. CASE REPORT: We report the case of a 26-year old man with intracranial hypertension revealing voluminous right frontal lesion. Surgical resection was performed and pathological examination found two distinct tumoral areas: a glioma-like area with calcification without mitosis; a second with pleomorphic glial cells with higher Mib index, high CD34 expression and endothelial proliferation. No necrosis was recorded. Molecular analyses revealed both IDH1 I113T and BRAF V600E mutations. Although this glioma was difficult to clarify, diagnosis of pleomorphic xanthoastrocytoma with anaplastic feature was suggested based on the association of some pathological feature (eosinophilic granular bodies, reticulin network and diffuse CD34 expression) and the BRAF V600E mutation.
CONCLUSION: We report a new IDH1 mutation associated with BRAF mutation in a very unusual glial tumor.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BRAF mutation; Glioma; IDH1 mutation; Pleomorphic xanthoastrocytoma

Mesh:

Substances:

Year:  2014        PMID: 24857351     DOI: 10.1016/j.jns.2014.05.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage.

Authors:  Wei Wang; Maode Wang; Haitao Jiang; Tuo Wang; Rong Da
Journal:  BMC Neurol       Date:  2021-05-12       Impact factor: 2.474

Review 2.  Oncogenic BRAF Alterations and Their Role in Brain Tumors.

Authors:  Felix Behling; Jens Schittenhelm
Journal:  Cancers (Basel)       Date:  2019-06-08       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.